Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update
Completed recent IPO raising approximately
On track for multiple IND filings
Recent Business Highlights
- Strengthened Leadership Team with Key Appointments. Added Dr.
Michael Lotzeas chief cellular therapy officer and Dr. Robert Brownas vice president of clinical development to help advance protein modulating drug candidates and cell therapy programs into the clinic. Also enhanced the financial team with the addition of Dr. Jason Kantoras senior vice president, finance and investment strategy.
- Completed an Initial Public Offering (IPO) in
July 2020raising approximately $238.5 millionin gross proceeds: On July 23, 2020, Nurixannounced the pricing of its IPO of 11,000,000 shares of common stock, at a public offering price of $19.00 per share. In addition, the underwriters subsequently exercised their option to purchase 1,550,000 additional shares of common stock. The net proceeds to Nurix from the offering were approximately $218.1 million, after deducting underwriting discounts, commissions and offering expenses.
- Business Continuity:
Nurixis executing upon its business objectives for 2020 and beyond and is on track to complete and file several investigational new drug applications (INDs), even accounting for the impact of the COVID-19 pandemic. Nurixcontinues to monitor the impact of the pandemic on its operations and the operations of its suppliers, vendors and business partners.
“Following our successful initial public offering and with our strategic collaborations, we believe we have the resources needed to steadily advance a broad and deep portfolio of protein modulation drug candidates,” said Dr.
Upcoming Program Highlights
- NX-2127: The Company’s lead drug candidate from its protein degradation portfolio, NX-2127, is an orally available degrader of Bruton’s tyrosine kinase (BTK) with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies. The Company expects to file an IND for NX-2127 with the
U.S. Food and Drug Administration(FDA) in late fourth quarter of 2020 or the first quarter of 2021 (expected timing of IND submissions here and throughout the press release are based on calendar year quarters).
- NX-1607: The Company’s lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available inhibitor of Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) for immuno-oncology indications. The Company expects to file an IND for NX-1607 with the FDA in the third quarter of 2021.
- NX-5948: The Company’s second drug candidate from its protein degradation portfolio, NX-5948, is an orally available BTK degrader designed without IMiD activity for certain B-cell malignancies, autoimmune diseases and related diseases such as graft-versus-host disease. The Company anticipates filing an IND with the FDA in the second half of 2021.
- DeTIL-0255: The Company’s lead candidate in its cellular therapy portfolio, DeTIL-0255, is a drug-enhanced adoptive cellular therapy. The Company anticipates filing an IND with the FDA in the second half of 2021.
Fiscal Third Quarter 2020 Financial Highlights
Collaboration revenue for the three months ended
Research and development expenses for the three months ended
General and administrative expenses for the three months ended
Net loss attributed to common stockholders for the three months ended
Cash, Cash Equivalents and Investments: As of
Forward Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective product candidates; the timing of our planned IND submissions for our product candidates; the planned timing and conduct of our clinical trial programs for our product candidates, preclinical activities, research and development costs, current and prospective collaborations; the potential advantages of our DELigase™ platform and product candidates; the extent to which our scientific approach and DELigase™ platform may potentially address a broad range of diseases; the estimated size of the market for our product candidates; and the timing and success of our development and commercialization of our anticipated product candidates are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions regarding the future of the Company’s business, future plans and strategies, its development plans, its preclinical results and other future conditions. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, performance or events and circumstances could differ materially from those expressed or implied in our forward-looking statements due to a variety of factors, including risks and uncertainties related to our ability to advance our product candidates, obtain regulatory approval of and ultimately commercialize our product candidates, the timing and results of preclinical and clinical trials, our ability to fund development activities and achieve development goals, the impact of the COVID-19 pandemic on our business, our ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in our final prospectus pursuant to Rule 424(b)(4) filed with the
Condensed consolidated statements of operations
(in thousands, except share and per share amounts)
|Three Months Ended|
|Research and development||18,939||11,008|
|General and administrative||4,338||2,184|
|Total operating expenses||23,277||13,192|
|Loss from operations||(19,192||)||(2,612||)|
|Interest and other income, net||675||195|
|Loss before provision (benefit) for income taxes||(18,517||)||(2,417||)|
|Provision (benefit) for income taxes||—||10|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.59||)||$||(0.66||)|
|Weighted-average number of shares outstanding, basic and diluted||31,383,936||3,667,335|
Condensed consolidated balance sheets
|Cash and cash equivalents||$||265,527||$||34,816|
|Income tax receivable||3,856||—|
|Prepaid expenses and other current assets||5,990||1,634|
|Total current assets||364,089||39,354|
|Property and equipment, net||6,532||3,871|
|Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)|
|Accrued and other current liabilities||7,102||4,927|
|Deferred revenue, current||30,299||9,612|
|Total current liabilities||41,012||16,137|
|Deferred revenue, net of current portion||62,374||35,693|
|Other long-term liabilities||868||1,737|
|Redeemable convertible preferred stock||—||48,195|
|Accumulated other comprehensive income (loss)||138||(2||)|
|Total stockholders’ equity (deficit)||307,620||(57,714||)|
|Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)||$||411,874||$||44,048|
Source: Nurix Therapeutics, Inc.